INVITED REVIEW
Transcriptional mechanisms of acute lung injury

Jie Fan, Richard D. Ye, and Asrar B. Malik

Department of Pharmacology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois 60612


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MOLECULAR BIOLOGY OF NF-kappa B
BACTERIA-INDUCED NF-kappa B...
ROLE OF NF-kappa B IN...
MODULATION OF NF-kappa B ACTIVATION...
INTERACTIONS BETWEEN NF-kappa B AND...
SUMMARY
REFERENCES

Acute lung injury occurs as a result of a cascade of cellular events initiated by either infectious or noninfectious inflammatory stimuli. An elevated level of proinflammatory mediators combined with a decreased expression of anti-inflammatory molecules is a critical component of lung inflammation. Expression of proinflammatory genes is regulated by transcriptional mechanisms. Nuclear factor-kappa B (NF-kappa B) is one critical transcription factor required for maximal expression of many cytokines involved in the pathogenesis of acute lung injury. Activation and regulation of NF-kappa B are tightly controlled by a complicated signaling cascade. In acute lung injury caused by infection of bacteria, Toll-like receptors play a central role in initiating the innate immune system and activating NF-kappa B. Anti-inflammatory cytokines such as interleukin-10 and interleukin-13 have been shown to suppress inflammatory processes through inhibiting NF-kappa B activation. NF-kappa B can interact with other transcription factors, and these interactions thereby lead to greater transcriptional selectivity. Modification of transcription is likely to be a logical therapeutic target for acute lung injury.

nuclear factor-kappa B; transcription factor; cytokine; pulmonary inflammation


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MOLECULAR BIOLOGY OF NF-kappa B
BACTERIA-INDUCED NF-kappa B...
ROLE OF NF-kappa B IN...
MODULATION OF NF-kappa B ACTIVATION...
INTERACTIONS BETWEEN NF-kappa B AND...
SUMMARY
REFERENCES

THE LUNG IS AN IMPORTANT TARGET ORGAN for systemic inflammatory mediators released after major trauma (6, 39, 44) and severe infection (113, 118). Acute respiratory distress syndrome (ARDS), clinically manifested as inflammatory lung injury of very rapid onset, is characterized by intractable respiratory dysfunction. This syndrome is associated with hypoxemia, reduced lung compliance, and diffuse infiltrations (13). Neutrophils sequestered in the lung play a central role in the pathogenesis of ARDS (50). Lung neutrophil accumulation seen in ARDS is thought to occur as a result of a cascade of cellular events initiated by either infectious or noninfectious inflammatory stimuli. Local activation of resident cells in the lung interstitium and alveolus, primarily macrophages, leads to elaboration of several proinflammatory cytokines such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta and chemokines including IL-8 and macrophage inflammatory protein (MIP)-2alpha (35, 37, 47, 87). These mediators act in concert to promote neutrophil sequestration by activating endothelial cell adhesion molecule expression and to induce migration of neutrophils into the interstitium and alveolar space where they propagate inflammation and injury through the release of reactive oxygen species (ROS) and proteolytic enzymes (155). A counterinflammatory response in the lungs is also initiated with the release of anti-inflammatory cytokines such as IL-10, IL-4, IL-13, IL-1 receptor antagonist (IL-1RA), and transforming growth factor (TGF)-beta (36, 47, 109). Elevated levels of proinflammatory mediators combined with decreased expression of anti-inflammatory molecules correlate with the magnitude of lung injury and its outcome (108). The imbalance between proinflammatory and anti-inflammatory mechanisms is a critical component of lung inflammation.

The signals that lead to increased gene expression and biosynthesis of proinflammatory mediators by airspace inflammatory and epithelial cells are thus of considerable interest. An understanding of the expression of genes, in particular the transcriptional apparatus usually located in the upstream region of the gene promoter, is required to explain the regulation of expression of proinflammatory genes. Nuclear factor (NF)-kappa B is one such critical transcription factor required for maximal expression of many cytokines involved in the pathogenesis of ARDS. NF-kappa B, first identified by Sen and Baltimore (124), functions to enhance the transcription of a variety of genes, including cytokines and growth factors, adhesion molecules, immunoreceptors, and acute-phase proteins (a list of genes containing NF-kappa B sites in their promoters is shown in Table 1). Under resting condition, NF-kappa B functions in regulating the expression of genes involved in normal immunologic responses such as the generation of antibody light chains and other immunoregulatory molecules (124, 152). NF-kappa B activation is necessary for an intact host defense response, whereas excessive activation of NF-kappa B results in overly exuberant inflammatory injury of lungs and other organs (17, 18, 40).

                              
View this table:
[in this window]
[in a new window]
 
Table 1.   Lung injury relevant genes regulated by NF-kappa B

In this review, we focus on the recent progress in our understanding of the role of NF-kappa B and interactions between NF-kappa B and other transcription factors in the pathogenesis of acute lung injury.


    MOLECULAR BIOLOGY OF NF-kappa B
TOP
ABSTRACT
INTRODUCTION
MOLECULAR BIOLOGY OF NF-kappa B
BACTERIA-INDUCED NF-kappa B...
ROLE OF NF-kappa B IN...
MODULATION OF NF-kappa B ACTIVATION...
INTERACTIONS BETWEEN NF-kappa B AND...
SUMMARY
REFERENCES

The NF-kappa B family of transcription factors. NF-kappa B belongs to the Rel family of proteins that are ubiquitous transcription factors sharing a common structural motif for DNA binding and dimerization (10). Although, for the sake of simplicity, NF-kappa B is often referred to as a single entity, it is, in reality, a complex mixture of homodimers and heterodimers, all with distinct characteristics and biological properties. The cloning of NF-kappa B family members has revealed five distinct subunits homologous to the protooncogene c-Rel and the Drosophila melanogaster morphogen dorsal: NF-kappa B1 (p50/105), NF-kappa B2 (p52/100), Rel A (p65), Rel B, and c-Rel itself (10, 134). These subunits are all highly related over an ~300-residue amino-terminal DNA binding and dimerization domain termed the Rel homology domain.

Activation of NF-kappa B. NF-kappa B is normally sequestered in the cytoplasm through its association with an inhibitor protein called inhibitory kappa B (Ikappa B), which masks the nuclear translocation signal and thus prevents NF-kappa B from entering the nucleus. NF-kappa B activation represents the terminal step in a signal transduction pathway leading from the cell surface to the nucleus. On exposure of the cell to activation signals such as the binding of lipopolysaccharide (LPS), TNF-alpha , or IL-1beta to cell surface receptors, the Ikappa B protein is phosphorylated on serine-32 and serine-36, ubiquinated, and degraded in proteasomes. After being freed from association with Ikappa B, the NF-kappa B complex moves to the nucleus where it binds to specific sequences in the promoter/enhancer regions of genes.

A wide variety of extracellular stimuli can trigger the activation of NF-kappa B, and the list of NF-kappa B inducers is rapidly expanding. Well-characterized inducers include proinflammatory cytokines (11), bacterial and viral products (8, 17, 160), and ROS. Many of the agents that activate NF-kappa B, such as TNF-alpha , IL-1beta , and LPS, also increase the cellular production of ROS by mitochondria (115) and play significant roles in the pathophysiology of acute lung injury. ROS have been recognized as important inducers of gene expression via NF-kappa B. Evidence for cellular oxidative signaling involvement in the activation of NF-kappa B is based on four key observations: 1) antioxidants such as pyrrolidine dithiocarbamate and N-acetylcysteine (NAC) abolish LPS-induced activation of NF-kappa B (73, 77, 78, 120, 161), 2) in vitro administration of H2O2 to cells stimulates activation of NF-kappa B (92), 3) NAC blocks activation of NF-kappa B in animal models of ARDS and improves lung function in patients with ARDS (16, 59, 140), and 4) overexpression of antioxidant enzymes such as manganese superoxide dismutase or glutathione peroxidase abolishes NF-kappa B activation induced by TNF-alpha , LPS, phorbol esters, and H2O2 (65, 81). Recently, however, Bowie and O'Neill (21), after reviewing the evidence for the oxidative stress model, concluded that in most cases the role of oxidative stress in NF-kappa B activation is at best facilitatory rather than causal. Furthermore, some studies show that redox activation of NF-kappa B is likely dependent on the nature of the mediator and selectivity of the signaling pathways activated as well as on the specific cell type (reviewed on Ref. 57). Indeed, the molecular basis for this regulation of NF-kappa B activation by ROS is poorly understood. It is clear, however, that NF-kappa B induction is mainly dependent on phosphorylation and degradation of Ikappa B (4, 86, 125). A recent study (55) provided evidence that there are also other optional NF-kappa B activating pathways such as tyrosine phosphorylation of Ikappa B.

NF-kappa B inhibitors and their regulation. The various forms of Ikappa B include Ikappa B-alpha , Ikappa B-beta , Ikappa B-epsilon , and Bcl-3 (10, 45, 153). In addition, p105, which is the precursor of p50, and p100, which is the precursor of p52, can bind Rel A and thus function as NF-kappa B inhibitors (31, 83, 97). The COOH-terminal portions of p105 and p100 have been designated Ikappa B-gamma and Ikappa B-delta , respectively. These inhibitory units contain multiple copies of ankyrin repeat domains that allow interaction with NF-kappa B in a configuration that masks the nuclear localization signal domains of NF-kappa B, thereby preventing nuclear transport (7). Signaling pathways leading to NF-kappa B activation converge on phosphorylation, ubiquitination, and degradation of Ikappa Bs (except Bcl-3), which unmask the nuclear localization signal leading to translocation of NF-kappa B/Rel dimers into the nucleus (4, 86, 125). Ikappa Bs are also active in the nucleus. Ikappa B-alpha and Ikappa B-beta interact with p50/p65 NF-kappa B heterodimers in the nucleus as in the cytoplasm, inhibiting transcriptional activity of NF-kappa B (4, 144). In experiments examining NF-kappa B activation in the lung, levels of Ikappa B-alpha in the nucleus as well as in the cytoplasm were elevated in a mixed population of intraparenchymal lung cells after hemorrhagic shock in association with NF-kappa B nuclear translocation (94). These findings suggest that 1) Ikappa B-alpha is upregulated by NF-kappa B and 2) other Ikappa B proteins contribute to NF-kappa B activation in the lung after blood loss.

Bcl-3 is an unusual Ikappa B protein in that it cannot only inhibit nuclear NF-kappa B complexes but also bind to p50 and p52 dimers on DNA and form a complex with transactivating activity (19, 46). The highest expression of Bcl-3 is found in lymph nodes and spleen, and as such, Bcl-3 has been shown to play a critical role in antigen-specific T cell immunity (9, 14, 20). However, a recent study (46) showed that Bcl-3 levels are increased after hemorrhage in intraparenchymal lung cells, suggesting that such alterations in Bcl-3 can contribute to the observed increased expression of NF-kappa B-dependent genes in the lungs.

Ikappa B phosphorylation requires Ikappa B kinase (IKK) activation (26, 154). Two closely related IKKs have been identified and cloned (34, 91, 112, 154, 158) and are referred to as IKK-alpha and IKK-beta . IKK-alpha and IKK-beta are 52% identical in their amino acids. Both kinases directly phosphorylate Ser32 and Ser36 of Ikappa B-alpha , and overexpression of each wild-type kinase leads to NF-kappa B activation (154). The activities of IKK-alpha and IKK-beta are stimulated by TNF-alpha , IL-1beta , and LPS treatment (91, 101). However, targeted deletion of the murine IKK-alpha and IKK-beta revealed different functions of these kinases. Whereas mice lacking IKK-beta had a defective response to inflammatory cytokines, mice lacking IKK-alpha displayed developmental defects (53, 71, 72). IKK-alpha and IKK-beta form a heterodimer that can interact directly with the upstream kinase NF-kappa B-inducing kinase (NIK) (112). These three kinases are considered to be present in the large 177-kDa Ikappa B kinase complex (26, 29). The IKK-gamma /NF-kappa B essential modulator was cloned by genetic complementation of an HTLV-1 Tax-transformed rat fibroblast cell line (156) and by biochemical purification (90, 117). IKK-gamma is essential for NF-kappa B activation by LPS, TNF-alpha , IL-1beta , or phorbol 12-myristate 13-acetate. Deletions of either the amino terminus or carboxy terminus of IKK-gamma blocked NF-kappa B activation (90, 117). IKK-gamma is composed of coiled-coil motifs including a leucine zipper (117) through which it presumably recruits upstream activators to the IKK complex. An amino-terminal alpha -helical region of IKK-gamma is responsible for interacting with a carboxy-terminal domain of IKK-alpha and IKK-beta . Overexpression of this IKK-gamma -interacting domain could block association of IKK-alpha ,beta with IKK-gamma and thereby inhibit cytokine-induced NF-kappa B activation (85).

Shimada et al. (133) reported a novel LPS-inducible IKK referred to as IKK-i. IKK-i shares 30% identity with IKK-alpha or IKK-beta . IKK-i is expressed mainly in immune cells and is induced in response to proinflammatory cytokines such as TNF-alpha , IL-1beta , and IL-6 as well as to LPS. Another molecule, IKK-associated protein, was suggested to be a scaffold protein that binds to NIK and IKKs and assembles them into an active kinase complex (29). Overexpression of IKK-associated protein inhibited TNF-alpha - and IL-1beta -induced NF-kappa B reporter activity (29), indicating its role in regulating the activity of Ikappa B. Moreover, Pomerantz and Baltimore (111) have identified another novel kinase, TBK1, related to IKK-alpha or IKK-beta and 48% identical to IKK-i, that associates with the TNF receptor-associated factor (TRAF)-binding protein TANK. TBK1 mediates NF-kappa B activation by TRAF-2, TRAF-5, TRAF-6, and TANK. TBK1 forms a complex with TANK and TRAF-2 that functions upstream from the NIK-IKK complex, but TBK1 does not appear to be required for the activation of NF-kappa B by TNF-alpha , IL-1beta , or CD14. Thus TANK and TBK1 probably belong to a separate pathway induced by different stimuli.

Nakano et al. (96) showed that mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1 (MEKK1), which constitutes the c-Jun NH2-terminal kinase/stress-activated protein kinase pathway, also activates NF-kappa B. The overexpression of MEKK1 preferentially stimulated the kinase activity of IKK-beta , which resulted in phosphorylation of Ikappa Bs (96). In contrast, overexpression of NIK comparably stimulates kinase activities of both IKK-alpha and IKK-beta , suggesting a qualitative difference between NIK- and MEKK1-mediated NF-kappa B activation pathways (96). The dominant negative mutant of MEKK1, on the other hand, partially blocks activation of IKK by TNF-alpha (98). Furthermore, MEKK1 appears to act in parallel to NIK, leading to synergistic activation of the IKK complex. The formation of the MEKK1-IKK complex versus the NIK-IKK complex may provide a molecular basis for the regulation of the IKK complex by various extracellular signals (98). These results suggest that NIK and MEKK1 can independently activate the IKK complex, and the kinase activities of IKK-alpha and IKK-beta are differentially regulated by two upstream kinases, NIK and MEKK1, both of which are responsive to distinct stimuli. Another group, Zhao and Lee (159), showed that MEKK2 and MEKK3 can activate in vivo IKK-alpha and IKK-beta , induce site-specific Ikappa B-alpha phosphorylation, and activate a NF-kappa B reporter gene. In addition, dominant negative versions of either IKK-alpha or IKK-beta abolished NF-kappa B activation induced by MEKK2 or MEKK3, thereby providing evidence that these IKKs mediate the NF-kappa B-inducing activities of these MEKKs. In contrast, other mitogen-activated protein kinase kinase kinases, including MEKK4, apoptosis signal-regulated kinase 1, and mixed lineage kinase 3, failed to induce activation of the NF-kappa B pathway.

An alternative mechanism of NF-kappa B activation through tyrosine phosphorylation but not through degradation of Ikappa B-alpha has also been reported (55). Stimulation of Jurkat T cells with the protein tyrosine phosphatase inhibitor and T cell activator pervanadate led to NF-kappa B activation (55). Pervanadate induced Ikappa B-alpha phosphorylation, and NF-kappa B activation required the expression of the T cell tyrosine kinase p56ick. Tyrosine phosphorylation of Ikappa B-alpha represents a proteolysis-independent mechanism of NF-kappa B activation that directly couples NF-kappa B to cellular tyrosine kinase. By site-specific mutagenesis and deletion analysis, Singh et al. (135) identified Tyr42 on Ikappa B-alpha as the phospho acceptor site. On investigating the mechanism by which pervanadate inhibits the degradation of Ikappa B-alpha , they showed in an in vitro reconstitution system that tyrosine-phosphorylated Ikappa B-alpha was protected from degradation. This study demonstrated that inducible phosphorylation and degradation of Ikappa B-alpha are negatively regulated by phosphorylation at Tyr42, thereby preventing NF-kappa B activation. The findings reveal an important interaction between these two pathways.

In the signaling of TNFalpha - or IL-1beta -induced NF-kappa B activation, the serine/threonine kinase Akt/protein kinase B has been identified as another important signaling component (38). Akt kinase is normally activated via the phosphoinositide 3-OH-kinase signaling pathway. Ozes et al. (104), working with epithelial cells, showed that TNF-alpha activated Akt and that inhibition of Akt blocked the TNF-alpha -induced activation of NF-kappa B, indicating that Akt associates with IKK-alpha and mediates its phosphorylation. Figure 1 provides a summary of the mechanisms of Ikappa B regulation outlined above.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 1.   Pathways of inhibitory kappa B (Ikappa B) regulation showing the upstream components signaling phosphorylation of Ikappa B and the release of nuclear factor (NF)-kappa B. TRAF, tumor necrosis factor (TNF) receptor-associated factor; NIK, NF-kappa B-inducing kinase; MEKK, mitogen-activated protein kinase kinase kinase; IKK, Ikappa B kinase; IKAP, IKK-associated protein; P, phosphorylation.


    BACTERIA-INDUCED NF-kappa B ACTIVATION: ROLE OF TOLL-LIKE RECEPTORS
TOP
ABSTRACT
INTRODUCTION
MOLECULAR BIOLOGY OF NF-kappa B
BACTERIA-INDUCED NF-kappa B...
ROLE OF NF-kappa B IN...
MODULATION OF NF-kappa B ACTIVATION...
INTERACTIONS BETWEEN NF-kappa B AND...
SUMMARY
REFERENCES

Infection with microbial pathogens and septicemia are major causes of acute lung injury. Major causative agents include gram-negative and/or gram-positive bacteria. Septic shock and acute lung injury follow a pattern in which one or more products of microbial pathogens such as the endotoxin of gram-negative bacteria, diverse membrane components of gram-positive bacteria, and nonmethylated CpG-rich sequences of bacterial DNA activate the innate immune system. This system represents the immediate host defense mechanism that involves the secretion of cytokines and other mediators with antimicrobial effects. It is well documented that phylogenetically conserved signaling mechanisms provide an immediate cellular reaction that utilizes NF-kappa B at the center of its first line of defense (89). The recognition of a pathogen is mediated by a set of germ line-encoded receptors referred to as pattern-recognition receptors, which directly recognize invariant molecular structures (pathogen-associated molecular patterns). These are shared by large groups of microorganisms (56, 88). The three functional classes of pattern-recognition receptors are signaling receptors, endocytic receptors, and secreted proteins. Studies over the past few years have demonstrated that a family of signaling receptors, known as the Toll-like receptors (TLRs), plays a crucial role in Drosophila and mammalian host defense. In both organisms, TLRs activate intracellular signaling, notably via NF-kappa B. At least nine TLRs have been identified in humans, but only three of them have been characterized as interacting with a ligand of bacterial origin (89, 116, 142). TLR2 is a receptor for peptidoglycan and lipopeptide from gram-positive bacteria and zymosan from yeast. TLR4 recognizes LPS from gram-negative bacteria (reviewed in Ref. 102). It was recently shown that TLR9 is a putative receptor for bacterially derived CpG DNA (51). All members of the Toll family are membrane proteins that span the membrane once and share similar extracellular domains, which include 18-31 leucine-rich repeats and similar cytoplasmic domains of ~200 amino acids. Interestingly, the latter domain is also similar to the cytoplasmic domain of the IL-1 receptor [Toll/IL-1 receptor homologous region (TIR)]. The cytoplasmic domains of the Toll family define a subclass of TIR domains. The TIR domain of human TLR4, for example, is 32% identical to Drosophila Toll but less similar (20% identical) to the TIR domain of the IL-1 receptor.

Specific components of microbial cell walls are strong activators of innate immune responses. Human pathogen-associated molecular patterns such as LPS of gram-negative bacteria and peptidoglycan and lipoteichoic acid components of gram-positive bacteria trigger the production of IL-1beta , TNF-alpha (103, 122, 141, 157), and IL-6 (74) as well as of cyclooxygenase metabolites (114). Recent genetic and biochemical experiments have highlighted the critical role of TLRs in LPS-induced NF-kappa B activation (27, 60, 100). Importantly, the responsiveness of TLRs to LPS is dependent on LPS binding protein and CD14 (121, 139). On binding of LPS to TLRs via CD14, a number of molecules are recruited to the receptor to mediate NF-kappa B activation (Fig. 2). First, the adaptor molecule myeloid differentiation factor 88 (MyD88) binds to the receptor and interacts through its death domain with the protein kinase IL-1 receptor-associated kinase (IRAK), which, in turn, recruits the adaptor TRAF-6 to the receptor complex (49). The importance of MyD88 in LPS signaling was confirmed by analysis of MyD88-deficient mice, which are normally highly resistant to LPS-induced shock (62). Evolutionarily conserved signaling intermediate in Toll pathways (ECSIT) bridges TRAF-6 to MEKK1. This protein is specific for the Toll/IL-1 pathway and is a regulator of MEKK1 processing (64). Expression of wild-type ECSIT accelerates the processing of MEKK1, whereas a dominant negative fragment of ECSIT blocks MEKK1 processing and activation of NF-kappa B (64). A recent study (3) indicated that stimulation of TLR2 by Staphylococcus aureus induces NF-kappa B activation through the small GTPases Rac1 and Cdc42.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 2.   Signaling pathway linking Toll-like receptor (TLR) to NF-kappa B. On binding of lipopolysaccharide (LPS) to TLRs via CD14, the adaptor molecule myeloid differentiation factor 88 (MyD88) binds to the receptor and interacts through its death domain with the interleukin (IL)-1 receptor-associated kinase (IRAK), which, in turn, recruits the adaptor TRAF-6 and the evolutionarily conserved signaling intermediate in Toll pathways (ECSIT) to the receptor complex. Downstream components MEKK1, MEKK2, and MEKK3 or NIK, which are activated by TAK1, link the receptor complex and phosphorylation of IKK-alpha and IKK-beta in IKK complex. IKK complex phosphorylates Ikappa B-alpha , Ikappa B-beta , and Ikappa B-epsilon at amino-terminal serines and results in degradation of the inhibitors by the ubiquitin-proteasome pathway and the subsequent release of NF-kappa B. LBP, LPS binding protein.

Resuscitated hemorrhagic shock is believed to promote the development of lung injury by priming the immune system for an exaggerated inflammatory response to a second, often trivial, stimulus, the so-called "two-hit hypothesis" (41, 95). In recent studies, a rodent model of LPS-induced lung injury after resuscitated hemorrhagic shock was used to examine the regulation of TLR4 gene and protein expression in vivo and to evaluate the impact of its regulation on the development of inflammation (Fan J and Rotstein OD, unpublished data). The studies have demonstrated that intratracheal LPS alone induces a rapid reduction of TLR4 mRNA in the whole lung and recovered alveolar macrophages. This effect appeared to be due to a lowering of TLR4 mRNA stability by ~69%. In contrast, although shock and resuscitation alone have no effect on TLR4 mRNA levels, they markedly alter the response to LPS. Specifically, the antecedent shock prevented the LPS-induced reduction in TLR4 mRNA levels in whole lung tissue and alveolar macrophages. This reversal can be explained by the ability of prior resuscitated shock to prevent the destabilization of TLR4 mRNA by LPS as well as to augment LPS-stimulated TLR4 gene transcription compared with LPS alone. Oxidant stress related to shock or resuscitation appears to contribute to the regulation of TLR4 mRNA. Supplementation of the resuscitation fluid with the antioxidant NAC reversed the ability of shock or resuscitation to preserve TLR4 mRNA levels after LPS. TLR4 protein levels in whole lung and surface expression on alveolar macrophages mirrored the changes seen in TLR4 mRNA. Furthermore, preservation of surface TLR4 receptors in LPS-treated alveolar macrophages recovered from shock or resuscitated animals correlated with enhanced NIK activity, NF-kappa B nuclear translocation, and inflammatory cytokine gene transcription (Fan J and Rotstein OD, personal communication). These data suggest that Tlr4 expression is controlled both transcriptionally as well as posttranscriptionally through altered mRNA stability and that changes in the local cellular microenvironment profoundly influence the net effect of these processes and, ultimately, cell responsiveness.


    ROLE OF NF-kappa B IN THE LUNG INFLAMMATORY RESPONSE
TOP
ABSTRACT
INTRODUCTION
MOLECULAR BIOLOGY OF NF-kappa B
BACTERIA-INDUCED NF-kappa B...
ROLE OF NF-kappa B IN...
MODULATION OF NF-kappa B ACTIVATION...
INTERACTIONS BETWEEN NF-kappa B AND...
SUMMARY
REFERENCES

Increasing evidence shows an important role for NF-kappa B in the pathogenesis of acute lung inflammation. In vitro studies have shown that NF-kappa B regulates gene expression of cytokines (TNF-alpha , IL-1beta ), chemokines [MIP-2, cytokine-induced neutrophil chemoattractant (CINC)], and adhesion molecules [intercellular adhesion molecule (ICAM)-1, E-selectin] (see Ref. 17). All of these factors play an important role in lung inflammatory injury (30). These in vitro findings are supported by a study in humans with ARDS (123) showing enhanced NF-kappa B activation in alveolar macrophages recovered by bronchoalveolar lavage. In addition, an in vivo study in animals (82) has shown an association between NF-kappa B activation and the expression of cytokines, chemokines, and vascular adhesion molecules (82). Recent studies in vivo demonstrated that lung NF-kappa B activation is suppressed by antioxidants (16, 76-78) or anti-inflammatory cytokines (70), resulting in decreased proinflammatory mediator expression and reduced inflammatory injury. Thus it appears that activation of NF-kappa B is central to the development of pulmonary inflammation and acute lung injury.

Lung neutrophil activation and apoptosis. Acute lung injury is characterized by the accumulation of neutrophils in the lungs, accompanied by the development of interstitial edema and an intense inflammatory response. A study (2) has addressed the role of neutrophils as early immune effectors in hemorrhage- or endotoxemia-induced lung injury. Mice were made neutropenic with cyclophosphamide or anti-neutrophil antibodies, and it was shown that endotoxemia- or hemorrhage-induced lung edema was significantly reduced in those animals (2). Activation of NF-kappa B after hemorrhage or endotoxemia was also diminished in the lungs of neutropenic mice compared with the lungs in nonneutropenic mice. These experiments show that neutrophils play a central role in initiating acute inflammatory responses and inducing tissue injury in lungs after hemorrhage or endotoxemia.

Proinflammatory cytokines such as IL-1beta , TNF-alpha , and MIP-2 can be produced by resident pulmonary cell populations, including alveolar macrophages and vascular endothelium (63, 143). Neutrophils that accumulate in the lungs after endotoxemia or hemorrhage also appear to be a significant intrapulmonary source of IL-1beta and other immunoregulatory cytokines (107). Shenker and Abraham (132) demonstrated that activated NF-kappa B contributes to lung neutrophil accumulation and expression of IL-1beta , TNF-alpha , and MIP-2 mRNAs in lung neutrophils from endotoxemic or hemorrhaged mice.

In addition to enhancing transcription of immunomodulatory genes, NF-kappa B plays an important role in apoptosis, presumably by regulating the expression of genes important in regulating cell death (147). In particular, increased NF-kappa B activation results in decreased apoptosis and increased cell life spans. This effect of NF-kappa B activation is a potential determinant of acute lung injury. An increased number of activated neutrophils that generate ROS and proinflammatory cytokines is present in the lungs of patients with ARDS, and these neutrophils have decreased rates of apoptosis (84, 106, 107). In experimental models of acute lung injury secondary to hemorrhage or endotoxemia, NF-kappa B was activated in the lungs and apoptosis was reduced in the neutrophil population (106). Thus increased survival of proinflammatory neutrophils in the lungs of patients with ARDS secondary to NF-kappa B activation may perpetuate the pulmonary inflammatory response. Inhibition of NF-kappa B activation in patients with ARDS may not only reduce the expression of proinflammatory mediators but also speed the resolution of lung injury by decreasing the numbers of activated resident neutrophils.

Alveolar macrophages. Alveolar macrophages are strategically situated at the air-tissue interface in the alveoli and alveolar ducts and are therefore the first cells encountered by inhaled organisms and antigens in the lower respiratory tract. Alveolar macrophages not only act in their traditional role as phagocytes but also function as potent secretory cells. Alveolar macrophages, on appropriate simulation, can release a wide variety of biologically active products and thereby play an important role in regulating inflammatory reactions within the lung. Depletion of alveolar macrophages by intratracheal instillation of liposomes containing the compound dichloromethylene diphosphonate has been used to study alveolar macrophage functions in vivo (23, 30, 129). It has been shown with this technique that depletion of alveolar macrophages reduces lung production of TNF-alpha and neutrophil recruitment in a model of LPS-induced lung inflammation (12, 48). In a model of bacterial pneumonia (23), depletion of alveolar macrophages by dichloromethylene diphosphonate-liposomes unexpectedly caused increased lung production of TNF-alpha and increased lung neutrophil recruitment. Although the nature of the stimulus may dictate the function of alveolar macrophages, it appears from the latter study that sources of TNF-alpha other than alveolar macrophages, under special circumstances, are important to the development of lung inflammatory injury.

The mechanism of NF-kappa B activation during lung inflammatory injury is known to require TNF-alpha and IL-1beta , which operate as autocrine/paracrine stimulators of alveolar macrophages (69). Alveolar macrophage activation is generally an initial event in the genesis of lung inflammatory reactions. In a rat model of injury induced by intrapulmonary deposition of IgG immune complexes, Lentsch et al. (70) showed that early activation of alveolar macrophages occurred in an NF-kappa B-dependent manner. Furthermore, NF-kappa B activation in alveolar macrophages in vivo occurred before NF-kappa B activation in whole lung tissues, and depletion of alveolar macrophages attenuated NF-kappa B activation in whole lung tissues and decreased the bronchoalveolar lavage fluid content of proinflammatory mediators. In addition, lung instillation of TNF-alpha in alveolar macrophage-depleted rats induced NF-kappa B activation in whole lungs (68). These results indicate that the products of activated alveolar macrophages such as TNF-alpha are essential in stimulating nuclear translocation of NF-kappa B in other lung cell types.

Several other animal models have also been used to evaluate the role of NF-kappa B in the production of inflammatory events in alveolar macrophages. Blackwell et al. (18) described a rat model of neutrophilic lung inflammation after intraperitoneal endotoxin injection. In this model, endotoxin injection is followed by activation of NF-kappa B in alveolar macrophages and lung tissue (16, 18). Activation of NF-kappa B correlated with the expression of mRNA of CINC, a neutrophil chemotactic chemokine, and this was followed by an influx of neutrophils into the alveolar space (18, 41). In addition, blocking endotoxin-induced NF-kappa B activation in lung tissue resulted in decreased CINC mRNA expression and diminished neutrophilic lung inflammation (16). Fan et al. (40) used a "two-hit" model of resuscitated hemorrhagic shock followed by intratracheal LPS in the rodent to evaluate the cellular mechanisms underlying enhanced fibrin deposition in the alveolar space. The results demonstrated that shock alone has little effect on the procoagulant milieu of the lung, whereas it primed the lung for increased NF-kappa B activity and macrophage tissue factor-dependent procoagulant activity as well as enhanced plasminogen activator inhibitor in response to a small dose of LPS. These findings further support the concept that regulating NF-kappa B activation in alveolar macrophages can significantly inhibit inflammatory events. Although the importance of NF-kappa B in cytokine transcription has been established in animal models, only a few published studies have demonstrated a role for NF-kappa B in human alveolar macrophages. Schwartz et al. (123) reported that NF-kappa B in alveolar macrophages from patients with ARDS is activated to a significantly higher degree than in alveolar macrophages from critically ill patients with other diseases. In contrast, basal activation of NF-kappa B in alveolar macrophages from normal volunteers appeared to be minimal (42). This finding reinforces the earlier reports (54, 93) that IL-8 and TNF-alpha levels are increased in lung lavage samples from patients with ARDS.

Endothelial activation. Endothelial expression of molecules that mediate adhesion and signaling of leukocytes is the key to understanding the transcriptional mechanisms of acute lung injury (28, 43, 79, 110). A significant advance is the concept that only the activated endothelium participates in the inflammatory response (150). In lung injury, endothelial adhesion molecules have a role in recruiting inflammatory cells such as neutrophils and lymphocytes from the circulation to the site of inflammation. NF-kappa B regulates the expression of several genes that encode adhesion molecules such as ICAM-1, vascular cell adhesion molecule-1, and E-selectin. Cytokine-induced cell surface expression of E-selectin, vascular cell adhesion molecule-1, and ICAM-1 and the secretion of IL-8 as well as of other chemokines are regulated at the transcriptional level in endothelial cells by the binding of NF-kappa B to its putative site in the 5'-flanking sequences (8). NF-kappa B-dependent expression of these molecules is downregulated in endothelial cells by treatment with antioxidants (25). This finding suggests a central role for NF-kappa B in the activation of genes in endothelial cells, the products of which promote the adhesion and extravasation of leukocytes across the endothelial barrier.


    MODULATION OF NF-kappa B ACTIVATION IN LUNGS
TOP
ABSTRACT
INTRODUCTION
MOLECULAR BIOLOGY OF NF-kappa B
BACTERIA-INDUCED NF-kappa B...
ROLE OF NF-kappa B IN...
MODULATION OF NF-kappa B ACTIVATION...
INTERACTIONS BETWEEN NF-kappa B AND...
SUMMARY
REFERENCES

The regulation of inflammation by cytokines involves an intricate balance of pro- and anti-inflammatory mediators. The principal anti-inflammatory cytokines released in lung tissue include IL-1RA, IL-4, IL-6, IL-10, IL-11, IL-13, and TGF-beta . The soluble cytokine receptors TNF receptor p55, TNF receptor p75, and IL-1 receptor type 2; the membrane-bound IL-1 receptor type 2; and the IL-18 binding protein also have anti-inflammatory activities. However, only a few of these have been shown to involve in lung injury via interaction with NF-kappa B.

Intrapulmonary deposition of IgG immune complexes in rats causes alveolar macrophage activation and results in neutrophil-dependent parenchymal cell injury as characterized by increased pulmonary vascular permeability and alveolar hemorrhage (61, 151). Studies (32, 126-128) have identified IL-6, IL-10, IL-1RA, and IL-13 as endogenous regulators in this model of inflammatory lung injury. Lentsch et al. (70) showed that exogenously administered IL-4, IL-10, or IL-13 greatly attenuated the lung injury induced by IgG immune complexes and demonstrated that both IL-10 and IL-13 inhibited nuclear localization of NF-kappa B in alveolar macrophages and lung tissues in a manner associated with preserved expression of Ikappa B-alpha protein. These findings suggest that IL-10 and IL-13 reduce lung inflammation by preventing degradation of Ikappa B-alpha , thus inhibiting the activation of NF-kappa B.

Schottelius et al. (119) showed that IL-10 functions to block NF-kappa B activity at two levels, through 1) suppression of IKK activity and 2) inhibition of NF-kappa B DNA binding activity. To address the mechanism of action of IL-10, Wang et al. (149) tested the effects of IL-10 on different transcription factors including NF-kappa B, NF-IL-6, activator protein (AP)-1, AP-2, glucocorticoid receptor, cAMP response element binding protein (CREB), Oct-1, and Sp1. They found that IL-10 selectively prevented NF-kappa B activation, with the effect occurring rapidly and in a dose-dependent manner. Moreover, the effect was correlated with the cytokine synthesis inhibitory activity of IL-10. IL-10 inhibited chemokine expression (MIP-1alpha and MIP-2) by inducing both mRNA destabilization and NF-kappa B inhibition (130). However, IL-4, which also inhibited cytokine mRNA accumulation in monocytes, showed little inhibitory effect on LPS-induced NF-kappa B activation (149). Unlike IL-10, IL-4 enhanced mRNA degradation and failed to suppress cytokine gene transcription. These data point to distinct roles for IL-10 and IL-4 in inhibiting cytokine production by different mechanisms.

TGF-beta , a pleiotropic cytokine/growth factor, is believed to play a critical role in the modulation of inflammatory events. DiChiara et al. (33) demonstrated that exogenous TGF-beta 1 inhibited the expression of the proinflammatory adhesion molecule E-selectin in vascular endothelium exposed to inflammatory stimuli. This inhibitory effect occurred at the level of transcription of the E-selectin gene and was dependent on the action of Smad proteins, a class of intracellular signaling proteins mediating the cellular effects of TGF-beta 1 (33). Furthermore, this work demonstrated that Smad-mediated effects in endothelial cells resulted from a competitive interaction between Smad proteins activated by TGF-beta 1 and NF-kappa B activated by inflammatory stimuli (such as cytokines or bacterial LPS). This interaction is mediated by the transcriptional coactivator CREB-binding protein (CBP) (33). Augmentation of the limited amount of CBP present in endothelial cells (via overexpression) or selective disruption of Smad-CBP interactions (via a dominant negative strategy) effectively antagonized the ability of TGF-beta 1 to block proinflammatory E-selectin expression (33). These data demonstrate a potentially important interaction between TGFbeta -1-regulated Smad proteins and NF-kappa B that is regulated by inflammatory stimuli in endothelial cells.


    INTERACTIONS BETWEEN NF-kappa B AND OTHER TRANSCRIPTION FACTORS
TOP
ABSTRACT
INTRODUCTION
MOLECULAR BIOLOGY OF NF-kappa B
BACTERIA-INDUCED NF-kappa B...
ROLE OF NF-kappa B IN...
MODULATION OF NF-kappa B ACTIVATION...
INTERACTIONS BETWEEN NF-kappa B AND...
SUMMARY
REFERENCES

NF-kappa B can differentially regulate the expression of many genes involved in inflammatory processes with different functions, in different cell types, and at different times. This diversity arises from a delicately balanced network of protein-protein interactions. NF-kappa B activity is determined not only through its regulated nuclear localization signal but also by the cellular context. NF-kappa B interacts with a large number of heterologous transcription factors, and these interactions can select for specific NF-kappa B subunits and thereby lead to greater transcriptional selectivity. Figure 3 is a hypothetical schema for possible mechanisms by which NF-kappa B interacts with other transcription factors.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 3.   Hypothetical models for interaction between NF-kappa B and another transcription factor (TF). A: NF-kappa B binds to kappa B site and regulates target gene transcription without interaction with the other TF. B: the other TF, except NF-kappa B, binds to its specific binding sequence and initials gene transcription. C: NF-kappa B and the other TF bind to their specific binding sites and synergistically result in enhanced gene transcription (+). D: the other TF can stimulate NF-kappa B DNA binding and transactivation through kappa B elements in the absence of other TF sites. E: interaction between NF-kappa B and the other TF sometimes does not involve a precise promoter/enhancer organization or even require a kappa B element. F: the other TF may negatively regulate NF-kappa B transactivation (-).

AP-1 is one such transcription factor involved in the control of many inflammatory mediators. AP-1 is composed of protooncogene products as heterodimers of c-Fos and c-Jun or as c-Jun-c-Jun homodimers. Activated AP-1 completely disrupts the structure of the nucleosome (99) and is considered to be the important first step in the chromatin remodeling process involved in the initial binding of transcriptional factors to a nucleosomal template. Interestingly, the interactions between NF-kappa B and AP-1 sometimes do not involve a precise promoter/enhancer organization or even require a kappa B element. Fos and Jun can stimulate Rel A DNA binding and transactivation through kappa B elements in the absence of AP-1 sites, whereas Rel A can stimulate AP-1 DNA binding and activation through AP-1 sites in the absence of a kappa B element (137). Armstead et al. (5) reported that tissue factor mRNA level and protein activity in plasma and lungs were markedly increased after trauma and the increase was AP-1 and NF-kappa B activation dependent. However, other observations suggest that AP-1 and NF-kappa B can function independently from each other. Shenker and Abraham (131) studied the transcriptional mechanisms involved in regulating pulmonary cytokine expression after hemorrhage and showed activation of NF-kappa B and CREB but not of AP-1, CCAAT/enhancer binding protein-beta (C/EBP-beta ), or Sp1 in lung mononuclear cells isolated from mice. Liu et al. (75) also observed that the expression of TNF-alpha by NF-kappa B was independent of c-Jun in primary human macrophages. A 120-bp TNF-alpha promoter-reporter possessing binding sites for NF-kappa B (kappa B3), C/EBP-beta , and c-Jun was activated by cotransfection of plasmids expressing the wild-type version of each of these transcription factors. Dominant negative versions of NF-kappa B p65 and c-Jun but not of C/EBP-beta suppressed LPS-induced TNF-alpha secretion in primary human macrophages (75). NF-kappa B p50/p65 heterodimers were bound to the kappa B3 site and c-Jun was bound to the -103 AP-1 site of the TNF-alpha promoter after LPS stimulation. By transient transfection, NF-kappa B p65 and p50 were shown to synergistically activate the TNF-alpha promoter. In contrast, such synergy was not observed between NF-kappa B p65 or NF-kappa B p50 and c-Jun or C/EBP-beta even in the presence of the coactivator p300 (75). This result suggests that adjacent kappa B3 and AP-1 sites in the human TNF-alpha promoter contribute independently to the LPS-induced activation response. More work is needed to determine how AP-1 interacts with other transcriptional factors such as NF-kappa B and thereby controls the inflammatory responses resulting in acute lung injury.

The C/EBP family of transcription factors, together with AP-1 and activating transcription factor/CREB, belong to a class of DNA binding proteins termed bZIP proteins (146). These proteins are characterized by their leucine zipper structure and the adjacent DNA binding basic region, both located in the COOH-terminal portion of the proteins. Four members of the C/EBP family, C/EBP-alpha , C/EBP-beta , C/EBP-gamma , and C/EBP-delta (24), form homodimers and heterodimers with each other and bind with a similar affinity to various C/EBP binding sites (24, 66). Stein et al. (138) demonstrated a functional and physical association between NF-kappa B and C/EBP. These associations are characterized by 1) inhibition of NF-kappa B-induced expression of promoters containing NF-kappa B binding sites by the expression of C/EBP family members and 2) positive synergistic action of NF-kappa B family members with C/EBP family members on promoters containing C/EBP binding sites.

Evidence indicates that NF-kappa B subunits act in concert with members of the C/EBP family of transcription factors in regulating gene expression mediated by the multimerized c-Fos serum response element (138). Several functional NF-kappa B subunits (p50, p65, and c-Rel) interacted with three different isoforms of C/EBP (alpha , beta , and delta ) (138), indicating an interaction between these families and not merely a limited interaction between individual members. In another study (136), it was shown that C/EBP repressed NF-kappa B transactivation through kappa B elements, whereas NF-kappa B stimulated DNA binding and transactivation through C/EBP binding sites. The IL-8 promoter contains a region with binding sites for both NF-kappa B and C/EBP in close proximity that is required for TNF-alpha - and IL-1beta -mediated activation (136). NF-kappa B and C/EBP cooperatively bind this element and thereby induce the expression of IL-8 (136). Thus C/EBP specifically modulates NF-kappa B function and cooperatively stimulates the transcription of genes.

Binding elements for NF-kappa B and CREB are present in the enhancer/promoter regions of the immunoregulatory cytokine genes IL-1beta and TNF-alpha and have important functions in modulating transcription of these genes (9, 125, 145). NF-kappa B and CREB were activated in the lungs after endotoxemia or blood loss (16, 67, 131); however, precisely how these two transcription factors cooperate to control inflammatory gene transcription in acute lung injury remains unclear.

High-mobility group protein-1 (HMG-1) is a highly conserved protein with >95% amino acid identity between rodents and humans (80, 105). HMG-1 was initially identified as a nonhistone nuclear protein that binds to the narrow minor groove of the AT sequence-rich B form of DNA. HMG-1 has been implicated in the regulation of gene transcription and in stabilizing nucleosome formation (15, 52, 58, 80, 105). A study (148) showed that HMG-1 is a key late mediator of endotoxin lethality. HMG-1 given intratracheally produced acute inflammatory injury in the lungs, with neutrophil accumulation, development of lung edema, and increased pulmonary production of IL-1beta , TNF-alpha , and MIP-2 (1). In endotoxin-induced acute lung inflammation, administration of anti-HMG-1 antibody either before or after endotoxin challenge decreased the migration of neutrophils into the lungs and prevented pulmonary edema. These protective effects of the anti-HMG-1 antibody were specific because pulmonary levels of IL-1beta , TNF-alpha , or MIP-2 were not decreased after therapy with the anti-HMG-1 antibody (1), thus pointing to a role for HMG-1 as a distal mediator of acute inflammatory lung injury.

The experiments of Brickman et al. (22) revealed the interaction between HMG-1 protein and members of the NF-kappa B family. They showed that the Drosophila protein DSP1, a HMG-1/2-like protein, binds DNA cooperatively with NF-kappa B, the p50 subunit of NF-kappa B, and the Rel domain of Dorsal (22). This cooperativity is also apparent with other DNA molecules bearing consensus Rel protein binding sites. Moreover, the cooperativity observed in these DNA binding assays is paralleled by interactions between protein pairs in the absence of DNA. It is apparent from the work thus far that further studies addressing the significance of interactions of HMG-1 with NF-kappa B in the mechanism of acute lung injury will be important.

There is growing evidence that the regulation of gene expression is not mediated solely by the presence or absence of a particular set of transcription factors. The mechanisms regulating NF-kappa B activation, NF-kappa B by Ikappa B, and the interactions of NF-kappa B with other transcription factors are complex. Additional studies that make functional sense of this complexity will not only enhance our understanding of the role played by transcription factors in mediating lung inflammation and acute lung injury but will also lead to novel therapies directed against lung inflammation.


    SUMMARY
TOP
ABSTRACT
INTRODUCTION
MOLECULAR BIOLOGY OF NF-kappa B
BACTERIA-INDUCED NF-kappa B...
ROLE OF NF-kappa B IN...
MODULATION OF NF-kappa B ACTIVATION...
INTERACTIONS BETWEEN NF-kappa B AND...
SUMMARY
REFERENCES

Transcriptional activities in which the NF-kappa B family members play a central position are key to understanding the pathobiology of acute lung injury. Therefore, modification of transcription becomes a logical therapeutic target for acute lung injury. Activation of NF-kappa B and other transcription factors represents a complex network of finely balanced protein-protein interactions. The balance of proinflammatory to anti-inflammatory cytokines is regulated by a highly intricate network of transcription factors. Under pathological conditions, anti-inflammatory mediators provide insufficient control over proinflammatory activities. Despite the complexities inherent in the human immune response, therapeutic intervention with specific inhibitors of transcription signaling may have significant benefits in lung injury. Future studies in this area are likely to lead to novel therapies for the wide range of NF-kappa B-mediated inflammatory diseases including acute lung injury.


    FOOTNOTES

Address for reprint requests and other correspondence: J. Fan, Dept. of Pharmacology, Univ. of Illinois at Chicago College of Medicine, Chicago, IL 60612 (E-mail: jiefan{at}uic.edu).


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MOLECULAR BIOLOGY OF NF-kappa B
BACTERIA-INDUCED NF-kappa B...
ROLE OF NF-kappa B IN...
MODULATION OF NF-kappa B ACTIVATION...
INTERACTIONS BETWEEN NF-kappa B AND...
SUMMARY
REFERENCES

1.   Abraham, E, Arcaroli J, Carmody A, Wang H, and Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol 165: 2950-2954, 2000[Abstract/Free Full Text].

2.   Abraham, E, Carmody A, Shenkar R, and Arcaroli J. Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 279: L1137-L1145, 2000[Abstract/Free Full Text].

3.   Arbibe, L, Mira JP, Teusch N, Kline L, Guha M, Mackman N, Godowski PJ, Ulevitch RJ, and Knaus UG. Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat Immunol 1: 533-540, 2000[ISI][Medline].

4.   Arenzana-Seisdedos, F, Turpin P, Rodriguez M, Thomas D, Hay RT, Virelizier JL, and Dargemont C. Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci 110: 369-378, 1997[Abstract/Free Full Text].

5.   Armstead, VE, Opentanova IL, Minchenko AG, and Lefer AM. Tissue factor expression in vital organs during murine traumatic shock: role of transcription factors AP-1 and NF-kappaB. Anesthesiology 91: 1844-1852, 1999[ISI][Medline].

6.   Ashbaugh, DG, Bigelow DB, Petty TL, and Levine BE. Acute respiratory distress in adults. Lancet 2: 319-323, 1967[ISI][Medline].

7.   Baeuerle, PA. Pro-inflammatory signaling: last pieces in the NF-kappaB puzzle? Curr Biol 8: R19-R22, 1998[ISI][Medline].

8.   Baeuerle, PA, and Baichwal VR. NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 65: 111-137, 1997[ISI][Medline].

9.   Baeuerle, PA, and Baltimore D. NF-kappa B: ten years after. Cell 87: 13-20, 1996[ISI][Medline].

10.   Baldwin, AS, Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683, 1996[ISI][Medline].

11.   Barnes, PJ, and Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071, 1997[Free Full Text].

12.   Berg, JT, Lee ST, Thepen T, Lee CY, and Tsan MF. Depletion of alveolar macrophages by liposome-encapsulated dichloromethylene diphosphonate. J Appl Physiol 74: 2812-2819, 1993[Abstract].

13.   Bernard, GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, and Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149: 818-824, 1994[Abstract].

14.   Bhatia, K, Huppi K, McKeithan T, Siwarski D, Mushinski JF, and Magrath I. Mouse bcl-3: cDNA structure, mapping and stage-dependent expression in B lymphocytes. Oncogene 6: 1569-1573, 1991[ISI][Medline].

15.   Bianchi, ME, and Beltrame M. Flexing DNA: HMG-box proteins and their partners. Am J Hum Genet 63: 1573-1577, 1998[ISI][Medline].

16.   Blackwell, TS, Blackwell TR, Holden EP, Christman BW, and Christman JW. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J Immunol 157: 1630-1637, 1996[Abstract].

17.   Blackwell, TS, and Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 17: 3-9, 1997[Abstract/Free Full Text].

18.   Blackwell, TS, Holden EP, Blackwell TR, DeLarco JE, and Christman JW. Cytokine-induced neutrophil chemoattractant mediates neutrophilic alveolitis in rats: association with nuclear factor kappa B activation. Am J Respir Cell Mol Biol 11: 464-472, 1994[Abstract].

19.   Bours, V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, and Siebenlist U. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 72: 729-739, 1993[ISI][Medline].

20.   Bours, V, Franzoso G, Brown K, Park S, Azarenko V, Tomita-Yamaguchi M, Kelly K, and Siebenlist U. Lymphocyte activation and the family of NF-kappa B transcription factor complexes. Curr Top Microbiol Immunol 182: 411-420, 1992[Medline].

21.   Bowie, A, and O'Neill LA. Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 59: 13-23, 2000[ISI][Medline].

22.   Brickman, JM, Adam M, and Ptashne M. Interactions between an HMG-1 protein and members of the Rel family. Proc Natl Acad Sci USA 96: 10679-10683, 1999[Abstract/Free Full Text].

23.   Broug-Holub, E, Toews GB, van Iwaarden JF, Strieter RM, Kunkel SL, Paine R, III, and Standiford TJ. Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival. Infect Immun 65: 1139-1146, 1997[Abstract].

24.   Cao, Z, Umek RM, and McKnight SL. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev 5: 1538-1552, 1991[Abstract].

25.   Chen, CC, and Manning AM. Transcriptional regulation of endothelial cell adhesion molecules: a dominant role for NF-kappa B. Agents Actions Suppl 47: 135-141, 1995[Medline].

26.   Chen, ZJ, Parent L, and Maniatis T. Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell 84: 853-862, 1996[ISI][Medline].

27.   Chow, JC, Young DW, Golenbock DT, Christ WJ, and Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 274: 10689-10692, 1999[Abstract/Free Full Text].

28.   Cines, DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, and Stern DM. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91: 3527-3561, 1998[Free Full Text].

29.   Cohen, L, Henzel WJ, and Baeuerle PA. IKAP is a scaffold protein of the IkappaB kinase complex. Nature 395: 292-296, 1998[ISI][Medline].

30.   Collart, MA, Baeuerle P, and Vassalli P. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol Cell Biol 10: 1498-1506, 1990[ISI][Medline].

31.   Costello, R, Cerdan C, Lipcey C, Algarte M, Martin Y, Baeuerle PA, Olive D, and Imbert J. The role of NF-kappa B1 (p50/p105) gene expression in activation of human blood T-lymphocytes via CD2 and CD28 adhesion molecules. Cell Growth Differ 4: 947-954, 1993[Abstract].

32.   Crouch, LD, Shanley TP, Johson KJ, and Ward PA. IL-13 is transcriptionally expressed in IgG-immune complex-induced lung injury (Abstract). FASEB J 10: A1008, 1996.

33.   DiChiara, MR, Kiely JM, Gimbrone MA, Jr, Lee ME, Perrella MA, and Topper JN. Inhibition of E-selectin gene expression by transforming growth factor beta in endothelial cells involves coactivator integration of Smad and nuclear factor kappaB-mediated signals. J Exp Med 192: 695-704, 2000[Abstract/Free Full Text].

34.   DiDonato, JA, Hayakawa M, Rothwarf DM, Zandi E, and Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 388: 548-554, 1997[ISI][Medline].

35.   Donnelly, SC, Strieter RM, Kunkel SL, Walz A, Robertson CR, Carter DC, Grant IS, Pollok AJ, and Haslett C. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet 341: 643-647, 1993[ISI][Medline].

36.   Donnelly, SC, Strieter RM, Reid PT, Kunkel SL, Burdick MD, Armstrong I, Mackenzie A, and Haslett C. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. Ann Intern Med 125: 191-196, 1996[Abstract/Free Full Text].

37.   Donnelly, TJ, Meade P, Jagels M, Cryer HG, Law MM, Hugli TE, Shoemaker WC, and Abraham E. Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury. Crit Care Med 22: 768-776, 1994[ISI][Medline].

38.   Downward, J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10: 262-267, 1998[ISI][Medline].

39.   Faist, E, Baue AE, Dittmer H, and Heberer G. Multiple organ failure in polytrauma patients. J Trauma 23: 775-787, 1983[ISI][Medline].

40.   Fan, J, Kapus A, Li YH, Rizoli S, Marshall JC, and Rotstein OD. Priming for enhanced alveolar fibrin deposition after hemorrhagic shock: role of tumor necrosis factor. Am J Respir Cell Mol Biol 22: 412-421, 2000[Abstract/Free Full Text].

41.   Fan, J, Marshall JC, Jimenez M, Shek PN, Zagorski J, and Rotstein OD. Hemorrhagic shock primes for increased expression of cytokine-induced neutrophil chemoattractant in the lung: role in pulmonary inflammation following lipopolysaccharide. J Immunol 161: 440-447, 1998[Abstract/Free Full Text].

42.   Farver, CF, Raychaudhuri B, Buhrow LT, Connors MJ, and Thomassen MJ. Constitutive NF-kappaB levels in human alveolar macrophages from normal volunteers. Cytokine 10: 868-871, 1998[ISI][Medline].

43.   Fishman, AP, Fishman MC, Freeman BA, Gimbrone MA, Rabinovitch M, Robinson D, and Gail DB. Mechanisms of proliferative and obliterative vascular diseases. Insights from the pulmonary and systemic circulations. NHLBI Workshop summary. Am J Respir Crit Care Med 158: 670-674, 1998[Free Full Text].

44.   Fowler, AA, Hamman RF, Good JT, Benson KN, Baird M, Eberle DJ, Petty TL, and Hyers TM. Adult respiratory distress syndrome: risk with common predispositions. Ann Intern Med 98: 593-597, 1983[ISI][Medline].

45.   Franzoso, G, Bours V, Azarenko V, Park S, Tomita-Yamaguchi M, Kanno T, Brown K, and Siebenlist U. The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites. EMBO J 12: 3893-3901, 1993[Abstract].

46.   Fujita, T, Nolan GP, Liou HC, Scott ML, and Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. Genes Dev 7: 1354-1363, 1993[Abstract].

47.   Goodman, RB, Strieter RM, Martin DP, Steinberg KP, Milberg JA, Maunder RJ, Kunkel SL, Walz A, Hudson LD, and Martin TR. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 154: 602-611, 1996[Abstract].

48.   Hashimoto, S, Pittet JF, Hong K, Folkesson H, Bagby G, Kobzik L, Frevert C, Watanabe K, Tsurufuji S, and Wiener-Kronish J. Depletion of alveolar macrophages decreases neutrophil chemotaxis to Pseudomonas airspace infections. Am J Physiol Lung Cell Mol Physiol 270: L819-L828, 1996[Abstract/Free Full Text].

49.   Hatada, EN, Krappmann D, and Scheidereit C. NF-kappaB and the innate immune response. Curr Opin Immunol 12: 52-58, 2000[ISI][Medline].

50.   Heflin, AC, Jr, and Brigham KL. Prevention by granulocyte depletion of increased vascular permeability of sheep lung following endotoxemia. J Clin Invest 68: 1253-1260, 1981[ISI][Medline].

51.   Hemmi, H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, and Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745, 2000[ISI][Medline].

52.   Himes, SR, Reeves R, Attema J, Nissen M, Li Y, and Shannon MF. The role of high-mobility group I(Y) proteins in expression of IL-2 and T cell proliferation. J Immunol 164: 3157-3168, 2000[Abstract/Free Full Text].

53.   Hu, Y, Baud V, Delhase M, Zhang P, Deerinck T, Ellisman M, Johnson R, and Karin M. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science 284: 316-320, 1999[Abstract/Free Full Text].

54.   Hyers, TM, Tricomi SM, Dettenmeier PA, and Fowler AA. Tumor necrosis factor levels in serum and bronchoalveolar lavage fluid of patients with the adult respiratory distress syndrome. Am Rev Respir Dis 144: 268-271, 1991[ISI][Medline].

55.   Imbert, V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB, Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger P, Baeuerle PA, and Peyron JF. Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell 86: 787-798, 1996[ISI][Medline].

56.   Janeway, CA, Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54: 1-13, 1989[Medline].

57.   Janssen-Heininger, YM, Poynter ME, and Baeuerle PA. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. Free Radic Biol Med 28: 1317-1327, 2000[ISI][Medline].

58.   Jayaraman, L, Moorthy NC, Murthy KG, Manley JL, Bustin M, and Prives C. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev 12: 462-472, 1998[Abstract/Free Full Text].

59.   Jepsen, S, Herlevsen P, Knudsen P, Bud MI, and Klausen NO. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study. Crit Care Med 20: 918-923, 1992[ISI][Medline].

60.   Jiang, Q, Akashi S, Miyake K, and Petty HR. Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. J Immunol 165: 3541-3544, 2000[Abstract/Free Full Text].

61.   Johnson, KJ, and Ward PA. Acute immunologic pulmonary alveolitis. J Clin Invest 54: 349-357, 1974[ISI][Medline].

62.   Kawai, T, Adachi O, Ogawa T, Takeda K, and Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11: 115-122, 1999[ISI][Medline].

63.   Kelley, J. Cytokines of the lung. Am Rev Respir Dis 141: 765-788, 1990[ISI][Medline].

64.   Kopp, E, Medzhitov R, Carothers J, Xiao C, Douglas I, Janeway CA, and Ghosh S. ECSIT is an evolutionarily conserved intermediate in the Toll/IL-1 signal transduction pathway. Genes Dev 13: 2059-2071, 1999[Abstract/Free Full Text].

65.   Kretz-Remy, C, Mehlen P, Mirault ME, and Arrigo AP. Inhibition of I kappa B-alpha phosphorylation and degradation and subsequent NF-kappa B activation by glutathione peroxidase overexpression. J Cell Biol 133: 1083-1093, 1996[Abstract].

66.   Lamb, P, and McKnight SL. Diversity and specificity in transcriptional regulation: the benefits of heterotypic dimerization. Trends Biochem Sci 16: 417-422, 1991[ISI][Medline].

67.   Le Tulzo, Y, Shenkar R, Kaneko D, Moine P, Fantuzzi G, Dinarello CA, and Abraham E. Hemorrhage increases cytokine expression in lung mononuclear cells in mice: involvement of catecholamines in nuclear factor-kappaB regulation and cytokine expression. J Clin Invest 99: 1516-1524, 1997[Abstract/Free Full Text].

68.   Lentsch, AB, Czermak BJ, Bless NM, Van Rooijen N, and Ward PA. Essential role of alveolar macrophages in intrapulmonary activation of NF-kappaB. Am J Respir Cell Mol Biol 20: 692-698, 1999[Abstract/Free Full Text].

69.   Lentsch, AB, Czermak BJ, Bless NM, and Ward PA. NF-kappaB activation during IgG immune complex-induced lung injury: requirements for TNF-alpha and IL-1beta but not complement. Am J Pathol 152: 1327-1336, 1998[Abstract].

70.   Lentsch, AB, Shanley TP, Sarma V, and Ward PA. In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest 100: 2443-2448, 1997[Abstract/Free Full Text].

71.   Li, Q, Lu Q, Hwang JY, Buscher D, Lee KF, Izpisua-Belmonte JC, and Verma IM. IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev 13: 1322-1328, 1999[Abstract/Free Full Text].

72.   Li, Q, Van Antwerp D, Mercurio F, Lee KF, and Verma IM. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 284: 321-325, 1999[Abstract/Free Full Text].

73.   Li, Y, and Trush MA. Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production. Biochem Biophys Res Commun 253: 295-299, 1998[ISI][Medline].

74.   Lien, E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, Fenton MJ, Oikawa M, Qureshi N, Monks B, Finberg RW, Ingalls RR, and Golenbock DT. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 105: 497-504, 2000[Abstract/Free Full Text].

75.   Liu, H, Sidiropoulos P, Song G, Pagliari LJ, Birrer MJ, Stein B, Anrather J, and Pope RM. TNF-alpha gene expression in macrophages: regulation by NF-kappa B is independent of c-Jun or C/EBP beta. J Immunol 164: 4277-4285, 2000[Abstract/Free Full Text].

76.   Liu, SF, Ye X, and Malik AB. In vivo inhibition of nuclear factor-kappa B activation prevents inducible nitric oxide synthase expression and systemic hypotension in a rat model of septic shock. J Immunol 159: 3976-3983, 1997[Abstract].

77.   Liu, SF, Ye X, and Malik AB. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes. Circulation 100: 1330-1337, 1999[Abstract/Free Full Text].

78.   Liu, SF, Ye X, and Malik AB. Pyrrolidine dithiocarbamate prevents I-kappaB degradation and reduces microvascular injury induced by lipopolysaccharide in multiple organs. Mol Pharmacol 55: 658-667, 1999[Abstract/Free Full Text].

79.   Luscinskas, FW, and Gimbrone MA, Jr. Endothelial-dependent mechanisms in chronic inflammatory leukocyte recruitment. Annu Rev Med 47: 413-421, 1996[ISI][Medline].

80.   Maher, JF, and Nathans D. Multivalent DNA-binding properties of the HMG-1 proteins. Proc Natl Acad Sci USA 93: 6716-6720, 1996[Abstract/Free Full Text].

81.   Manna, SK, Zhang HJ, Yan T, Oberley LW, and Aggarwal BB. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappaB and activated protein-1. J Biol Chem 273: 13245-13254, 1998[Abstract/Free Full Text].

82.   Manning, AM, Bell FP, Rosenbloom CL, Chosay JG, Simmons CA, Northrup JL, Shebuski RJ, Dunn CJ, and Anderson DC. NF-kappa B is activated during acute inflammation in vivo in association with elevated endothelial cell adhesion molecule gene expression and leukocyte recruitment. J Inflamm 45: 283-296, 1995[ISI][Medline].

83.   Matthews, JR, Watson E, Buckley S, and Hay RT. Interaction of the C-terminal region of p105 with the nuclear localisation signal of p50 is required for inhibition of NF-kappa B DNA binding activity. Nucleic Acids Res 21: 4516-4523, 1993[Abstract].

84.   Matute-Bello, G, Liles WC, Radella F, 2nd, Steinberg KP, Ruzinski JT, Jonas M, Chi EY, Hudson LD, and Martin TR. Neutrophil apoptosis in the acute respiratory distress syndrome. Am J Respir Crit Care Med 156: 1969-1977, 1997[Abstract/Free Full Text].

85.   May, MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, and Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 289: 1550-1554, 2000[Abstract/Free Full Text].

86.   May, MJ, and Ghosh S. Signal transduction through NF-kappa B. Immunol Today 19: 80-88, 1998[ISI][Medline].

87.   Meduri, GU, Kohler G, Headley S, Tolley E, Stentz F, and Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest 108: 1303-1314, 1995[Abstract/Free Full Text].

88.   Medzhitov, R, and Janeway CA, Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91: 295-298, 1997[ISI][Medline].

89.   Medzhitov, R, Preston-Hurlburt P, and Janeway CA, Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397, 1997[ISI][Medline].

90.   Mercurio, F, Murray BW, Shevchenko A, Bennett BL, Young DB, Li JW, Pascual G, Motiwala A, Zhu H, Mann M, and Manning AM. IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex. Mol Cell Biol 19: 1526-1538, 1999[Abstract/Free Full Text].

91.   Mercurio, F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, Young DB, Barbosa M, Mann M, Manning A, and Rao A. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 278: 860-866, 1997[Abstract/Free Full Text].

92.   Meyer, M, Schreck R, and Baeuerle PA. H2O2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J 12: 2005-2015, 1993[Abstract].

93.   Miller, EJ, Cohen AB, Nagao S, Griffith D, Maunder RJ, Martin TR, Weiner-Kronish JP, Sticherling M, Christophers E, and Matthay MA. Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Am Rev Respir Dis 146: 427-432, 1992[ISI][Medline].

94.   Moine, P, Shenkar R, Kaneko D, Le Tulzo Y, and Abraham E. Systemic blood loss affects NF-kappa B regulatory mechanisms in the lungs. Am J Physiol Lung Cell Mol Physiol 273: L185-L192, 1997[Abstract/Free Full Text].

95.   Moore, FA, and Moore EE. Evolving concepts in the pathogenesis of postinjury multiple organ failure. Surg Clin North Am 75: 257-277, 1995[ISI][Medline].

96.   Nakano, H, Shindo M, Sakon S, Nishinaka S, Mihara M, Yagita H, and Okumura K. Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci USA 95: 3537-3542, 1998[Abstract/Free Full Text].

97.   Naumann, M, Nieters A, Hatada EN, and Scheidereit C. NF-kappa B precursor p100 inhibits nuclear translocation and DNA binding of NF-kappa B/rel-factors. Oncogene 8: 2275-2281, 1993[ISI][Medline].

98.   Nemoto, S, DiDonato JA, and Lin A. Coordinate regulation of IkappaB kinases by mitogen-activated protein kinase kinase kinase 1 and NF-kappaB-inducing kinase. Mol Cell Biol 18: 7336-7343, 1998[Abstract/Free Full Text].

99.   Ng, KW, Ridgway P, Cohen DR, and Tremethick DJ. The binding of a Fos/Jun heterodimer can completely disrupt the structure of a nucleosome. EMBO J 16: 2072-2085, 1997[Abstract/Free Full Text].

100.   Nomura, F, Akashi S, Sakao Y, Sato S, Kawai T, Matsumoto M, Nakanishi K, Kimoto M, Miyake K, Takeda K, and Akira S. Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol 164: 3476-3479, 2000[Abstract/Free Full Text].

101.   O'Connell, MA, Bennett BL, Mercurio F, Manning AM, and Mackman N. Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells. J Biol Chem 273: 30410-30414, 1998[Abstract/Free Full Text].

102.   O'Neill, L. Specificity in the innate response: pathogen recognition by Toll-like receptor combinations. Trends Immunol 22: 70, 2001[Medline].

103.   Opitz, B, Schroder NW, Spreitzer I, Michelsen KS, Kirschning CJ, Hallatschek W, Zahringer U, Hartung T, Gobel UB, and Schumann RR. Toll-like receptor (TLR)-2 mediates Treponema glycolipid and lipoteichoic acid (LTA)-induced NF-kappa B translocation. J Biol Chem 276: 22041-22047, 2001[Abstract/Free Full Text].

104.   Ozes, ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, and Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82-85, 1999[ISI][Medline].

105.   Parkkinen, J, Raulo E, Merenmies J, Nolo R, Kajander EO, Baumann M, and Rauvala H. Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem 268: 19726-19738, 1993[Abstract/Free Full Text].

106.   Parsey, MV, Kaneko D, Shenkar R, and Abraham E. Neutrophil apoptosis in the lung after hemorrhage or endotoxemia: apoptosis and migration are independent of interleukin-1beta. Chest 116: 67S-68S, 1999[Free Full Text].

107.   Parsey, MV, Tuder RM, and Abraham E. Neutrophils are major contributors to intraparenchymal lung IL-1 beta expression after hemorrhage and endotoxemia. J Immunol 160: 1007-1013, 1998[Abstract/Free Full Text].

108.   Parsons, PE. Mediators and mechanisms of acute lung injury. Clin Chest Med 21: 467-476, 2000[ISI][Medline].

109.   Parsons, PE, Moss M, Vannice JL, Moore EE, Moore FA, and Repine JE. Circulating IL-1ra and IL-10 levels are increased but do not predict the development of acute respiratory distress syndrome in at-risk patients. Am J Respir Crit Care Med 155: 1469-1473, 1997[Abstract].

110.   Pober, JS, and Cotran RS. The role of endothelial cells in inflammation. Transplantation 50: 537-544, 1990[ISI][Medline].

111.   Pomerantz, JL, and Baltimore D. NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J 18: 6694-6704, 1999[Abstract/Free Full Text].

112.   Regnier, CH, Song HY, Gao X, Goeddel DV, Cao Z, and Rothe M. Identification and characterization of an IkappaB kinase. Cell 90: 373-383, 1997[ISI][Medline].

113.   Repine, JE. Scientific perspectives on adult respiratory distress syndrome. Lancet 339: 466-469, 1992[ISI][Medline].

114.   Rhee, SH, and Hwang D. Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase. J Biol Chem 275: 34035-34040, 2000[Abstract/Free Full Text].

115.   Richter, C, Gogvadze V, Laffranchi R, Schlapbach R, Schweizer M, Suter M, Walter P, and Yaffee M. Oxidants in mitochondria: from physiology to diseases. Biochim Biophys Acta 1271: 67-74, 1995[ISI][Medline].

116.   Rock, FL, Hardiman G, Timans JC, Kastelein RA, and Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 95: 588-593, 1998[Abstract/Free Full Text].

117.   Rothwarf, DM, Zandi E, Natoli G, and Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 395: 297-300, 1998[ISI][Medline].

118.   Sauaia, A, Moore FA, Moore EE, Haenel JB, Read RA, and Lezotte DC. Early predictors of postinjury multiple organ failure. Arch Surg 129: 39-45, 1994[Abstract].

119.   Schottelius, AJ, Mayo MW, Sartor RB, and Baldwin AS, Jr. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 274: 31868-31874, 1999[Abstract/Free Full Text].

120.   Schreck, R, Meier B, Mannel DN, Droge W, and Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med 175: 1181-1194, 1992[Abstract].

121.   Schroder, NW, Opitz B, Lamping N, Michelsen KS, Zahringer U, Gobel UB, and Schumann RR. Involvement of lipopolysaccharide binding protein, CD14, and Toll-like receptors in the initiation of innate immune responses by Treponema glycolipids. J Immunol 165: 2683-2693, 2000[Abstract/Free Full Text].

122.   Schwandner, R, Dziarski R, Wesche H, Rothe M, and Kirschning CJ. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 274: 17406-17409, 1999[Abstract/Free Full Text].

123.   Schwartz, MD, Moore EE, Moore FA, Shenkar R, Moine P, Haenel JB, and Abraham E. Nuclear factor-kappa B is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit Care Med 24: 1285-1292, 1996[ISI][Medline].

124.   Sen, R, and Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46: 705-716, 1986[ISI][Medline].

125.   Sha, WC. Regulation of immune responses by NF-kappa B/Rel transcription factor. J Exp Med 187: 143-146, 1998[Free Full Text].

126.   Shanley, TP, Foreback JL, Remick DG, Ulich TR, Kunkel SL, and Ward PA. Regulatory effects of interleukin-6 in immunoglobulin G immune-complex-induced lung injury. Am J Pathol 151: 193-203, 1997[Abstract].

127.   Shanley, TP, Peters JL, Jones ML, Chensue SW, Kunkel SL, and Ward PA. Regulatory effects of endogenous interleukin-1 receptor antagonist protein in immunoglobulin G immune complex-induced lung injury. J Clin Invest 97: 963-970, 1996[Abstract/Free Full Text].

128.   Shanley, TP, Schmal H, Friedl HP, Jones ML, and Ward PA. Regulatory effects of intrinsic IL-10 in IgG immune complex-induced lung injury. J Immunol 154: 3454-3460, 1995[Abstract/Free Full Text].

129.   Shanley, TP, Schmal H, Warner RL, Schmid E, Friedl HP, and Ward PA. Requirement for C-X-C chemokines (macrophage inflammatory protein-2 and cytokine-induced neutrophil chemoattractant) in IgG immune complex-induced lung injury. J Immunol 158: 3439-3448, 1997[Abstract].

130.   Shanley, TP, Vasi N, and Denenberg A. Regulation of chemokine expression by IL-10 in lung inflammation. Cytokine 12: 1054-1064, 2000[ISI][Medline].

131.   Shenkar, R, and Abraham E. Hemorrhage induces rapid in vivo activation of CREB and NF-kappaB in murine intraparenchymal lung mononuclear cells. Am J Respir Cell Mol Biol 16: 145-152, 1997[Abstract].

132.   Shenkar, R, and Abraham E. Mechanisms of lung neutrophil activation after hemorrhage or endotoxemia: roles of reactive oxygen intermediates, NF-kappa B, and cyclic AMP response element binding protein. J Immunol 163: 954-962, 1999[Abstract/Free Full Text].

133.   Shimada, T, Kawai T, Takeda K, Matsumoto M, Inoue J, Tatsumi Y, Kanamaru A, and Akira S. IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases. Int Immunol 11: 1357-1362, 1999[Abstract/Free Full Text].

134.   Siebenlist, U, Franzoso G, and Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 10: 405-455, 1994[ISI].

135.   Singh, S, Darnay BG, and Aggarwal BB. Site-specific tyrosine phosphorylation of IkappaBalpha negatively regulates its inducible phosphorylation and degradation. J Biol Chem 271: 31049-31054, 1996[Abstract/Free Full Text].

136.   Stein, B, and Baldwin AS, Jr. Distinct mechanisms for regulation of the interleukin-8 gene involve synergism and cooperativity between C/EBP and NF-kappa B. Mol Cell Biol 13: 7191-7198, 1993[Abstract].

137.   Stein, B, Baldwin AS, Jr, Ballard DW, Greene WC, Angel P, and Herrlich P. Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J 12: 3879-3891, 1993[Abstract].

138.   Stein, B, Cogswell PC, and Baldwin AS, Jr. Functional and physical associations between NF-kappa B and C/EBP family members: a Rel domain-bZIP interaction. Mol Cell Biol 13: 3964-3974, 1993[Abstract].

139.   Su, GL, Klein RD, Aminlari A, Zhang HY, Steinstraesser L, Alarcon WH, Remick DG, and Wang SC. Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and toll-like receptor 4. Hepatology 31: 932-936, 2000[ISI][Medline].

140.   Suter, PM, Domenighetti G, Schaller MD, Laverriere MC, Ritz R, and Perret C. N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. Chest 105: 190-194, 1994[Abstract].

141.   Takeuchi, O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, and Akira S. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11: 443-451, 1999[ISI][Medline].

142.   Takeuchi, O, Kawai T, Sanjo H, Copeland NG, Gilbert DJ, Jenkins NA, Takeda K, and Akira S. TLR6: a novel member of an expanding toll-like receptor family. Gene 231: 59-65, 1999[ISI][Medline].

143.   Thomassen, MJ, Divis LT, and Fisher CJ. Regulation of human alveolar macrophage inflammatory cytokine production by interleukin-10. Clin Immunol Immunopathol 80: 321-324, 1996[ISI][Medline].

144.   Tran, K, Merika M, and Thanos D. Distinct functional properties of IkappaB alpha and IkappaB beta. Mol Cell Biol 17: 5386-5399, 1997[Abstract].

145.   Tsukada, J, Saito K, Waterman WR, Webb AC, and Auron PE. Transcription factors NF-IL6 and CREB recognize a common essential site in the human prointerleukin 1 beta gene. Mol Cell Biol 14: 7285-7297, 1994[Abstract].

146.   Vinson, CR, Sigler PB, and McKnight SL. Scissors-grip model for DNA recognition by a family of leucine zipper proteins. Science 246: 911-916, 1989[ISI][Medline].

147.   Wang, CY, Mayo MW, Korneluk RG, Goeddel DV, and Baldwin AS, Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680-1683, 1998[Abstract/Free Full Text].

148.   Wang, H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, and Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251, 1999[Abstract/Free Full Text].

149.   Wang, P, Wu P, Siegel MI, Egan RW, and Billah MM. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 270: 9558-9563, 1995[Abstract/Free Full Text].

150.   Ward, PA, and Hunninghake GW. Lung inflammation and fibrosis. Am J Respir Crit Care Med 157: S123-S129, 1998[ISI][Medline].

151.   Warner, RL, Paine R, 3rd, Christensen PJ, Marletta MA, Richards MK, Wilcoxen SE, and Ward PA. Lung sources and cytokine requirements for in vivo expression of inducible nitric oxide synthase. Am J Respir Cell Mol Biol 12: 649-661, 1995[Abstract].

152.   Weih, F, Carrasco D, Durham SK, Barton DS, Rizzo CA, Ryseck RP, Lira SA, and Bravo R. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 80: 331-340, 1995[ISI][Medline].

153.   Whiteside, ST, Epinat JC, Rice NR, and Israel A. I kappa B epsilon, a novel member of the I kappa B family, controls RelA and cRel NF-kappa B activity. EMBO J 16: 1413-1426, 1997[Abstract/Free Full Text].

154.   Woronicz, JD, Gao X, Cao Z, Rothe M, and Goeddel DV. IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science 278: 866-869, 1997[Abstract/Free Full Text].

155.   Worthen, GS, and Downey GP. Mechanisms of neutrophil mediated injury. In: ARDS Acute Respiratory Distress in Adults, edited by Evans TW, and Haslett C.. London: Chapman and Hall, 1996, p. 99-114.

156.   Yamaoka, S, Courtois G, Bessia C, Whiteside ST, Weil R, Agou F, Kirk HE, Kay RJ, and Israel A. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 93: 1231-1240, 1998[ISI][Medline].

157.   Yoshimura, A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, and Golenbock D. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 163: 1-5, 1999[Abstract/Free Full Text].

158.   Zandi, E, Rothwarf DM, Delhase M, Hayakawa M, and Karin M. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 91: 243-252, 1997[ISI][Medline].

159.   Zhao, Q, and Lee FS. Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-kappaB through IkappaB kinase-alpha and IkappaB kinase- beta. J Biol Chem 274: 8355-8358, 1999[Abstract/Free Full Text].

160.   Zhu, Z, Tang W, Ray A, Wu Y, Einarsson O, Landry ML, Gwaltney J, Jr, and Elias JA. Rhinovirus stimulation of interleukin-6 in vivo and in vitro. Evidence for nuclear factor kappa B-dependent transcriptional activation. J Clin Invest 97: 421-430, 1996[Abstract/Free Full Text].

161.   Ziegler-Heitbrock, HW, Sternsdorf T, Liese J, Belohradsky B, Weber C, Wedel A, Schreck R, Bauerle P, and Strobel M. Pyrrolidine dithiocarbamate inhibits NF-kappa B mobilization and TNF production in human monocytes. J Immunol 151: 6986-6993, 1993[Abstract/Free Full Text].


Am J Physiol Lung Cell Mol Physiol 281(5):L1037-L1050
1040-0605/01 $5.00 Copyright © 2001 the American Physiological Society